A012103: OPTIMICE-PCR: DE-ESCALATION OF THERAPY IN EARLY-STAGE TNBC PATIENTS WHO ACHIEVE PCR AFTER NEOADJUVANT CHEMOTHERAPY WITH CHECKPOINT INHIBITOR THERAPY (Location: Sioux Falls)

Objective

Clinical Trial Details >>

Principal Investigator(s)
Alexandra (Ally) Higgins, MD

Clinical Trial Categories

  • Cancer
  • Breast Cancer
Contact
Breast Research Coordinators at 605-322-1432
or breastresearch@avera.org

Location

  • Avera Cancer Institute — Sioux Falls
    1000 E 23rd St
    Suite 340
    Sioux Falls, SD 57105
    Main: 605-322-3000